# GPT 5.2 Review - Reviewer 3/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-21T16:28:59.823293
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_03b30a4f47ebb5f4006970f01bbb7c81979b9eb6233b994f0a
**Tokens:** 10055 in / 6054 out
**Response SHA256:** 2b131ece305269b7

---

## 1. FORMAT CHECK

**Length**
- **Fails top-journal norm.** The manuscript appears to be **~17 pages total including appendix figures** (page numbers shown through **p.17**). Main text ends around **p.14**, with references **p.15** and appendix **pp.16–17**. This is **below the requested 25+ pages** (excluding references/appendix) and below what AER/QJE/JPE/ReStud/Ecta/AEJ:EP typically require for a credible policy evaluation.

**References**
- **Inadequate and incomplete.** The bibliography lists **7 items** (p.15) and the text contains multiple **placeholder citations “(?)” and “(??)”** (e.g., Abstract and Introduction, pp.1–2; Methods, p.7; Discussion, p.12). This is not acceptable for a serious submission: it signals the literature review and factual claims are not properly sourced.

**Prose vs bullets**
- Major sections are mostly written in paragraphs (Intro pp.2–3; Discussion p.12; Conclusion pp.13–14).  
- Bullets are used appropriately for variable definitions in Data (p.5). **Pass** on this dimension.

**Section depth (3+ substantive paragraphs)**
- **Introduction:** Yes (pp.2–3).  
- **Institutional background:** Mostly yes (pp.3–4), though still thin for a top journal.  
- **Data:** Thin; much of it is definitions and brief description (pp.5–6).  
- **Results/Discussion:** Results are short relative to expectations; Discussion exists but is also short and partially speculative (pp.8–13). Overall, sections do not have the depth expected for general-interest outlets.

**Figures**
- Figures show axes and data (e.g., Figure 1 p.6; Figure 2 p.9; Figure 3 p.10; Figure 5 p.16/17).  
- However, several figures look like **draft-quality** (font sizes/legibility; figure notes are minimal; event-study figure lacks reporting of underlying sample/cohorts per event time).

**Tables**
- Tables contain numeric values (Table 2 p.6; Table 3 p.8; Table 4 p.11).  
- **But “N” reporting is inconsistent/unclear** (Table 3 lists “State-years 78–212” which is not an acceptable way to report sample size for a main regression table).

**Bottom line on format:** Not ready for a top journal: too short; placeholders in citations; references far too sparse; tables/figures not yet publication standard.

---

## 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard Errors
- **Mostly pass**: Table 3 (p.8) reports SEs in parentheses; Table 4 (p.11) reports SEs; placebo and other estimates in text sometimes include SEs (e.g., placebo p.11). Event-study figure shows confidence intervals (p.9).
- **But**: many reported quantities in figures are not accompanied by a table of coefficients+SEs, and key estimates are sometimes described narratively without full inference.

### (b) Significance testing (as you specified)
- **Fails your stated bar**: the paper **does not report p-values, t-stats, or significance stars** in the main tables (Table 3 has SEs and CIs, but no p-values/stars; Table 4 likewise).  
- Even if one can infer significance from 95% CIs, **your criterion explicitly requires p-values/t-stats/stars**. Under that rule, **this is a fail**.

### (c) Confidence intervals
- **Partial pass**: Table 3 includes 95% CIs (p.8). Event-study figure uses 95% CI bands (p.9).  
- But additional primary outcomes (eye exam, fair/poor health) are listed in Data (p.5) yet not fully reported with complete tables of estimates and CIs.

### (d) Sample sizes (N)
- **Fails**: N is not reported in a regression-standard way. Table 3 lists “States 54” and “State-years 78–212” (p.8), which is ambiguous and not acceptable.  
- For CS(2021) group-time ATTs, you should still report (i) number of treated states used per cohort-time cell, (ii) number of control states used, and (iii) effective N (or at least the panel N used for each outcome).

### (e) DiD with staggered adoption
- **Pass in principle, but with important implementation concerns.**
  - The paper correctly flags TWFE bias with staggered adoption (p.7) and uses **Callaway & Sant’Anna** and **Sun-Abraham** (pp.7–9). That is the right family of estimators.
  - However, there are **serious design and measurement problems** (see Identification below) that undermine the credibility of the resulting inference.

### (f) RDD
- Not applicable.

**Methodology verdict:** Even ignoring your “must show p-values/stars” rule, the **inference and reporting are not yet at top-journal standard** (unclear N; design-based concerns; weak transparency on event-time sample composition; questionable aggregation). Under your explicit criteria, **this fails and is unpublishable as written**.

---

## 3. IDENTIFICATION STRATEGY

### Core identification claim
The paper uses staggered DiD to estimate the effect of state insulin OOP caps on insulin use among diabetics in BRFSS (2019–2022). This is potentially interesting, but **the identification is currently not credible** for several reasons:

1. **Parallel trends is violated in the authors’ own event study.**  
   - Figure 2 (p.9) shows **statistically significant pre-treatment coefficients at t−2 and t−3**, which the paper acknowledges. This is a first-order threat.  
   - The discussion (“anticipation effects or, more likely, violations…”, p.9) is not enough. A top-journal paper must either (i) restore credibility with a design that plausibly satisfies assumptions, or (ii) bound conclusions using robust-to-pretrends methods.

2. **Treatment is mismeasured / weakly assigned.**  
   - The cap applies primarily to **state-regulated fully insured plans**, not ERISA self-insured employers (p.4). Yet the outcome is **all diabetics**, including uninsured, Medicare, Medicaid, and self-insured workers (pp.5–6). This produces severe attenuation and heterogeneous compliance.
   - Texas is effective **Sept 2021** (Table 1, p.4). If treatment is coded at the **year** level without using BRFSS interview month, you mechanically introduce misclassification (most of 2021 is untreated), creating attenuation and potentially spurious “pretrends.”

3. **Outcome is not well aligned with the policy margin.**
   - “Are you now taking insulin?” among **all diagnosed diabetics** (p.5) mixes (i) Type 1, (ii) insulin-requiring Type 2, and (iii) Type 2 not clinically indicated for insulin.  
   - Price caps should primarily affect **adherence/intensity** among insulin users (rationing, days covered, dose skipping), not necessarily the extensive margin of “any insulin use.” The paper notes this (p.12) but does not remedy it.

4. **Aggregation to state-year is a major self-inflicted limitation.**
   - The authors aggregate BRFSS microdata to **state-year weighted means** “to address computational constraints” (p.5). With ~220,000 diabetic observations, computational constraints are not persuasive in 2026.  
   - Aggregation collapses rich within-state variation (insurance status, income, age, high-deductible exposure) that is essential to isolate the impacted population and run triple-difference designs.

5. **COVID-period confounding is not handled seriously.**
   - The sample is 2019–2022 (pp.5–6), exactly the period when healthcare utilization changed dramatically and heterogeneously by state. A top-journal DiD paper in this window must do much more: explicit controls, interactions, sensitivity checks, or alternative outcomes not driven by utilization shocks.

### Placebos and robustness
- There is a placebo and leave-one-out (pp.10–11), but these are **not sufficient** given violated pretrends.
- “Heterogeneity by cap level” (Table 4, p.11) uses an **interacted TWFE**, which the paper itself motivates as problematic under staggered adoption (p.7). That robustness is not aligned with the stated econometric standard.

### Conclusion discipline
- The paper is relatively careful in tone (pp.12–14), but the abstract still frames “suggest either no effect or modest positive effect,” which is too strong given identification failure. A top outlet would require more disciplined partial identification / sensitivity analysis.

**Identification verdict:** **Not credible as written**; the paper’s own event study undermines the design, and key treatment/outcome measurement choices likely drive nulls and instability.

---

## 4. LITERATURE (Missing references + BibTeX)

### Methodology literature (missing and important)
You cite Callaway–Sant’Anna, Goodman-Bacon, Sun–Abraham (p.15). That is necessary but not sufficient for a 2026 DiD paper with violated pretrends and few clusters.

You should add (at minimum):

1) **Borusyak, Jaravel & Spiess (2021)** — imputation DiD estimator; useful alternative and benchmark.
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}
```

2) **Roth (and coauthors) on pretrends sensitivity / honest DiD** — essential given significant pre-period coefficients.
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

3) **de Chaisemartin & D’Haultfœuille** — alternative robust DiD estimators for staggered adoption.
```bibtex
@article{deChaisemartinDHaultfoeuille2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

4) **Few-cluster inference / wild bootstrap** — relevant with ~54 clusters and only 18 treated states.
```bibtex
@article{CameronGelbachMiller2008,
  author  = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title   = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year    = {2008},
  volume  = {90},
  number  = {3},
  pages   = {414--427}
}
```

### Health/policy literature (thin and partially absent)
The paper makes factual claims about insulin price growth, rationing, and policy effects with placeholders (pp.1–3, 12). A top journal will expect engagement with:

- **Empirical insulin affordability / rationing literature** beyond Herkert et al. (already cited).
- **Cost-sharing and drug adherence** literature (Medicare Part D, high-deductible plans, value-based insurance design).
- **Direct prior work on state insulin caps** using claims data (you cite a Texas A&M Health report-like reference; you need peer-reviewed or working-paper equivalents and broader state evidence if it exists).

Examples to consider adding (illustrative; you must verify the best matches to your exact claims/data):
- RAND Health Insurance Experiment / cost-sharing classic:
```bibtex
@article{ManningNewhouse1987,
  author  = {Manning, Willard G. and Newhouse, Joseph P. and Duan, Naihua and Keeler, Emmett B. and Leibowitz, Arleen and Marquis, M. Susan},
  title   = {Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment},
  journal = {American Economic Review},
  year    = {1987},
  volume  = {77},
  number  = {3},
  pages   = {251--277}
}
```

- Survey weights / regression guidance (important since you use BRFSS weights):
```bibtex
@article{SolonHaiderWooldridge2015,
  author  = {Solon, Gary and Haider, Steven J. and Wooldridge, Jeffrey M.},
  title   = {What Are We Weighting For?},
  journal = {Journal of Human Resources},
  year    = {2015},
  volume  = {50},
  number  = {2},
  pages   = {301--316}
}
```

**Why these are relevant:** your main threats are (i) violated pretrends and (ii) weak linkage between policy and measured outcome; the DiD sensitivity and weighting/inference literatures are directly relevant to making credible statements.

### Positioning and contribution
- The paper claims to be “first quasi-experimental evaluation” of downstream outcomes. Given the rapid growth of this policy area, that claim must be **carefully verified** and tightly scoped (e.g., “using BRFSS self-reported insulin use among diabetics, 2019–2022”). Otherwise it will be challenged immediately by referees.

---

## 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Generally paragraph-based in major sections. **Pass**.

### (b) Narrative flow
- The motivation is clear (pp.2–3), and the institutional background is helpful (pp.3–4).
- However, the **arc is not yet compelling enough for a general-interest journal** because the central empirical result is: “small, imprecise, and pretrends fail.” In that scenario, the paper must either:
  1) pivot to a design that *does* identify something credible, or  
  2) reframe as a careful descriptive/sensitivity analysis paper with honest bounds.
- Right now it sits awkwardly between “causal evaluation” and “descriptive null with problems.”

### (c) Sentence-level quality
- Serviceable, but often reads like a policy report rather than a polished journal paper. Examples:
  - Frequent hedging without delivering a decisive analytical resolution (pp.9–13).
  - Several claims are unsupported due to placeholders, which also harms readability/credibility.

### (d) Accessibility
- Econometric choices are explained at a high level (pp.7–8).  
- But key practical issues (ERISA exemption, partial-year exposure, BRFSS measurement) are acknowledged only briefly; non-specialists will not understand why the design is so fragile.

### (e) Figures/tables publication quality
- Draft quality; needs clearer notes (sample definition; weighting; event-time support; number of states contributing to each point; treatment definition exact timing).

**Writing verdict:** readable, but not “beautifully written” or sufficiently authoritative for AER/QJE/JPE/ReStud/Ecta/AEJ:EP. The bigger issue is that the writing cannot compensate for weak identification and incomplete scholarship.

---

## 6. CONSTRUCTIVE SUGGESTIONS (How to make it publishable)

### A. Fix treatment definition and exploit interview month (high priority)
- Use BRFSS **interview month** and exact effective dates. Code treatment at month level (or drop transition months / use partial exposure weights). Texas Sept 2021 is a clear case where annual coding is inappropriate.

### B. Stop aggregating to state-year; use microdata and target affected populations
Run individual-level models with survey weights and state-clustered SEs, focusing on groups plausibly affected:
- Restrict to **privately insured, under-65** (state-regulated markets are primarily non-Medicare).
- Use BRFSS insurance variables to implement **triple differences**:
  - Treated vs untreated states × post × **private insurance** (or “fully insured proxy” if available).
  - Use Medicare beneficiaries (65+) as a **within-state placebo/control group** (caps generally won’t affect Medicare; and IRA Medicare cap only starts 2023, outside your window).

### C. Measure outcomes that match the mechanism
If you stay in BRFSS, “any insulin use” is too blunt. Options:
- Use BRFSS questions on **cost barriers** (if available in core or modules): e.g., “could not see doctor due to cost,” “skipped meds due to cost” (not insulin-specific but informative).
- Consider outcomes plausibly affected by adherence:
  - ER visits, hospitalizations, DKA (but BRFSS won’t capture well). Better: **HCUP state inpatient/ED**, CDC WONDER mortality, or all-payer claims where possible.

### D. Address pretrends with modern sensitivity/bounding
Given significant pre-coefficients (p.9), you need:
- **Honest DiD / bounded deviations from parallel trends** (Rambachan–Roth).
- Show robustness to:
  - alternative control groups (never-treated only vs not-yet-treated),
  - alternative event-study normalizations,
  - cohort-specific trends (with caution),
  - reweighting/matching on pre-trends and covariates.

### E. Treatment intensity: incorporate ERISA/self-insured share
Construct state-year exposure intensity using:
- MEPS-IC or KFF estimates of **share in self-insured plans** / fully insured.  
Then estimate dose-response: effect should be larger where a larger share is exposed.

### F. Inference upgrades
- With ~54 clusters and 18 treated states, report:
  - **wild cluster bootstrap p-values**,
  - randomization/permutation inference (assign placebo adoption years),
  - and/or leave-one-state-out for *CS* estimates (not just TWFE).

### G. Expand time window
A 2019–2022 window is extremely short, and COVID dominates. If feasible:
- Extend through **2024/2025** BRFSS.
- But then you must handle **IRA Medicare $35 cap in 2023** carefully (e.g., exclude 65+; or explicitly model it as a separate national shock interacting with Medicare coverage).

### H. Scholarship and claims discipline
- Replace every “(?)” and “(??)” with real citations.
- Verify and properly cite insulin price trend numbers and rationing prevalence.
- Replace “first study” claims with narrowly verifiable statements.

---

## 7. OVERALL ASSESSMENT

**Key strengths**
- Important policy question; clear motivation (pp.2–3).
- Correctly recognizes TWFE problems under staggered adoption and attempts modern estimators (pp.7–9).
- Transparent about threats (pretrends; measurement; COVID), which is intellectually honest (pp.9–13).

**Critical weaknesses**
1. **Identification failure**: significant pretrends in the event study (p.9) with no serious corrective strategy.  
2. **Treatment/outcome mismatch**: policy affects a subset (state-regulated plans), outcome is broad and binary among all diabetics (pp.4–6).  
3. **Short and COVID-dominated sample** (2019–2022) with limited post periods.  
4. **Reporting/inference not at top-journal standard**: unclear N; no p-values/stars; thin tables; ambiguous “state-years 78–212” (p.8).  
5. **References and citations are not acceptable**: placeholders and a 7-item bibliography (p.15).

**Specific improvements**
- Rebuild around a credible exposed-vs-unexposed design (triple diff, under-65 privately insured, intensity by fully-insured share), use microdata with proper inference, add honest DiD sensitivity, and expand years.

---

DECISION: REJECT AND RESUBMIT